TABLE OF CONTENTS
| | | | Volume 31, Issue 4 (April 2017) | | In this issue Reviews Original Articles Letters to the Editor Correspondence
Also new AOP | | | | Reviews | Top | | Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptorsI Aldoss, R C Bargou, D Nagorsen, G R Friberg, P A Baeuerle and S J Forman Leukemia 2017 31: 777-787; advance online publication, December 28, 2016; 10.1038/leu.2016.391 Abstract | Full Text | | | | Proposed diagnostic criteria and classification of basophilic leukemias and related disordersP Valent, K Sotlar, K Blatt, K Hartmann, A Reiter, I Sadovnik, W R Sperr, P Bettelheim, C Akin, K Bauer, T I George, E Hadzijusufovic, D Wolf, J Gotlib, F-X Mahon, D D Metcalfe, H-P Horny and M Arock Leukemia 2017 31: 788-797; advance online publication, January 16, 2017; 10.1038/leu.2017.15 Abstract | Full Text | | | | Biological and clinical consequences of NPM1 mutations in AMLE M Heath, S M Chan, M D Minden, T Murphy, L I Shlush and A D Schimmer Leukemia 2017 31: 798-807; advance online publication, January 23, 2017; 10.1038/leu.2017.30 Abstract | Full Text | | Original Articles | Top | | ACUTE MYELOID LEUKEMIA | Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemiaN Narayan, L Morenos, B Phipson, S N Willis, G Brumatti, S Eggers, N Lalaoui, L M Brown, H J Kosasih, R C Bartolo, L Zhou, D Catchpoole, R Saffery, A Oshlack, G J Goodall and P G Ekert Leukemia 2017 31: 808-820; advance online publication, October 14, 2016; 10.1038/leu.2016.279 Abstract | Full Text | | | | ACUTE LYMPHOBLASTIC LEUKEMIA | Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrencesE Waanders, B Scheijen, M C J Jongmans, H Venselaar, S V van Reijmersdal, A H A van Dijk, A Pastorczak, R D A Weren, C E van der Schoot, M van de Vorst, E Sonneveld, N Hoogerbrugge, V H J van der Velden, B Gruhn, P M Hoogerbrugge, J J M van Dongen, A Geurts van Kessel, F N van Leeuwen and R P Kuiper Leukemia 2017 31: 821-828; advance online publication, October 13, 2016; 10.1038/leu.2016.277 Abstract | Full Text | | | | CHRONIC MYELOGENOUS LEUKEMIA | Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Sausslele, C T Dietz, M C Mu¨ller, E Eigendorff, C A Brendel, S K Metzelder, T H Bru¨mmendorf, C Waller, J Dengler, M E Goebeler, R Herbst, G Freunek, S Hanzel, T Illmer, Y Wang, T Lange, F Finkernagel, R Hehlmann, M Huber, A Neubauer, A Hochhaus, J Guilhot, F Xavier Mahon, M Pfirrmann and A Burchert Leukemia 2017 31: 829-836; advance online publication, January 11, 2017; 10.1038/leu.2017.9 Abstract | Full Text | | | | CHRONIC LYMPHOCYTIC LEUKEMIA | Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemiaB Stamatopoulos, A Timbs, D Bruce, T Smith, R Clifford, P Robbe, A Burns, D V Vavoulis, L Lopez, P Antoniou, J Mason, H Dreau and A Schuh Leukemia 2017 31: 837-845; advance online publication, October 31, 2016; 10.1038/leu.2016.307 Abstract | Full Text | | | | LYMPHOMA | High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) OPENK Fritsch, B Kasenda, E Schorb, P Hau, J Bloehdorn, R Möhle, S Löw, M Binder, J Atta, U Keller, H-H Wolf, S W Krause, G Heß, R Naumann, S Sasse, C Hirt, M Lamprecht, U Martens, A Morgner, J Panse, N Frickhofen, A Röth, C Hader, M Deckert, H Fricker, G Ihorst, J Finke and G Illerhaus Leukemia 2017 31: 846-852; advance online publication, November 15, 2016; 10.1038/leu.2016.334 Abstract | Full Text | | | | MULTIPLE MYELOMA, GAMMOPATHIES | The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myelomaS Manier, J T Powers, A Sacco, S V Glavey, D Huynh, M R Reagan, K Z Salem, M Moschetta, J Shi, Y Mishima, C Roche-Lestienne, X Leleu, A M Roccaro, G Q Daley and I M Ghobrial Leukemia 2017 31: 853-860; advance online publication, October 24, 2016; 10.1038/leu.2016.296 Abstract | Full Text | | | | MYELODYSPLASTIC SYNDROME | Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndromeN Hasegawa, M Oshima, G Sashida, H Matsui, S Koide, A Saraya, C Wang, T Muto, K Takane, A Kaneda, K Shimoda, C Nakaseko, K Yokote and A Iwama Leukemia 2017 31: 861-871; advance online publication, October 3, 2016; 10.1038/leu.2016.268 Abstract | Full Text | | | | Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapyG L Uy, E J Duncavage, G S Chang, M A Jacoby, C A Miller, J Shao, S Heath, K Elliott, T Reineck, R S Fulton, C C Fronick, M O'Laughlin, L Ganel, C N Abboud, A F Cashen, J F DiPersio, R K Wilson, D C Link, J S Welch, T J Ley, T A Graubert, P Westervelt and M J Walter Leukemia 2017 31: 872-881; advance online publication, October 14, 2016; 10.1038/leu.2016.282 Abstract | Full Text | | | | CHRONIC MYELOPROLIFERATIVE NEOPLASMS | Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendationsM Marchetti, G Barosi, F Cervantes, G Birgegård, M Griesshammer, C Harrison, R Hehlmann, J-J Kiladjian, N Kröger, M F McMullin, F Passamonti, A Vannucchi and T Barbui Leukemia 2017 31: 882-888; advance online publication, October 14, 2016; 10.1038/leu.2016.283 Abstract | Full Text | | | | Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisR F Schlenk, F Stegelmann, A Reiter, E Jost, N Gattermann, H Hebart, C Waller, A Hochhaus, U Platzbecker, P Schafhausen, I W Blau, W Verbeek, F H Heidel, M Werner, H Kreipe, V Teleanu, A Benner, H Döhner, M Grießhammer and K Döhner Leukemia 2017 31: 889-895; advance online publication, October 24, 2016; 10.1038/leu.2016.299 Abstract | Full Text | | | | A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence OPENA Tefferi, H K Al-Ali, G Barosi, T Devos, H Gisslinger, Q Jiang, J-J Kiladjian, R Mesa, F Passamonti, V Ribrag, G Schiller, A M Vannucchi, D Zhou, D Reiser, J Zhong and R P Gale for the RESUME trialists Leukemia 2017 31: 896-902; advance online publication, October 24, 2016; 10.1038/leu.2016.300 Abstract | Full Text | | | | STEM CELL TRANSPLANTATION | Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host diseaseM-T Rubio, M Bouillié, N Bouazza, T Coman, H Trebeden-Nègre, A Gomez, F Suarez, D Sibon, A Brignier, E Paubelle, S Nguyen-Khoc, M Cavazzana, O Lantz, M Mohty, S Urien and O Hermine Leukemia 2017 31: 903-912; advance online publication, October 14, 2016; 10.1038/leu.2016.281 Abstract | Full Text | | | | MOLECULAR TARGETS FOR THERAPY | MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemiaB Xu, Y Zhao, X Wang, P Gong and W Ge Leukemia 2017 31: 913-921; advance online publication, October 24, 2016; 10.1038/leu.2016.297 Abstract | Full Text | | | | TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION, CELL CYCLE | Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RASE Müller, S Bauer, T Stühmer, A Mottok, C-J Scholz, T Steinbrunn, D Brünnert, A Brandl, H Schraud, S Kreßmann, A Beilhack, A Rosenwald, R C Bargou and M Chatterjee Leukemia 2017 31: 922-933; advance online publication, September 30, 2016; 10.1038/leu.2016.264 Abstract | Full Text | | | | A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation OPENK Kollmann, W Warsch, C Gonzalez-Arias, F L Nice, E Avezov, J Milburn, J Li, D Dimitropoulou, S Biddie, M Wang, E Poynton, M Colzani, M R Tijssen, S Anand, U McDermott, B Huntly and T Green Leukemia 2017 31: 934-944; advance online publication, October 14, 2016; 10.1038/leu.2016.280 Abstract | Full Text | | | | Estrogen promotes megakaryocyte polyploidization via estrogen receptor beta-mediated transcription of GATA1C Du, Y Xu, K Yang, S Chen, X Wang, S Wang, C Wang, M Shen, F Chen, M Chen, D Zeng, F Li, T Wang, F Wang, J Zhao, G Ai, T Cheng, Y Su and J Wang Leukemia 2017 31: 945-956; advance online publication, October 17, 2016; 10.1038/leu.2016.285 Abstract | Full Text | | | | Transcriptional regulation of SPROUTY2 by MYB influences myeloid cell proliferation and stem cell properties by enhancing responsiveness to IL-3M Clarke, G Volpe, L Sheriff, D Walton, C Ward, W Wei, S Dumon, P García and J Frampton Leukemia 2017 31: 957-966; advance online publication, October 17, 2016; 10.1038/leu.2016.289 Abstract | Full Text | | Letters to the Editor | Top | | Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myelomaJ Bordini, S Galvan, M Ponzoni, M T S Bertilaccio, M Chesi, P L Bergsagel, C Camaschella and A Campanella Leukemia 2017 31: 967-970; advance online publication, November 24, 2016; 10.1038/leu.2016.346 Full Text | | | | Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patientsF Passamonti, B Mora, T Giorgino, P Guglielmelli, M Cazzola, M Maffioli, A Rambaldi, M Caramella, R Komrokji, J Gotlib, J J Kiladjian, F Cervantes, T Devos, F Palandri, V De Stefano, M Ruggeri, R Silver, G Benevolo, F Albano, D Caramazza, E Rumi, M Merli, D Pietra, R Casalone, T Barbui, L Pieri and A M Vannucchi Leukemia 2017 31: 970-973; advance online publication, November 25, 2016; 10.1038/leu.2016.351 Full Text | | | | NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML groupV Bisio, M Zampini, C Tregnago, E Manara, V Salsi, A Di Meglio, R Masetti, M Togni, D Di Giacomo, S Minuzzo, A Leszl, V Zappavigna, R Rondelli, C Mecucci, A Pession, F Locatelli, G Basso and M Pigazzi Leukemia 2017 31: 974-977; advance online publication, November 28, 2016; 10.1038/leu.2016.361 Full Text | | | | Baboon envelope pseudotyped lentiviral vectors: a highly efficient new tool to genetically manipulate T-cell acute lymphoblastic leukaemia-initiating cellsC Costa, G Hypolite, O Bernadin, C Lévy, F-L Cosset, V Asnafi, E Macintyre, E Verhoeyen and M Tesio Leukemia 2017 31: 977-980; advance online publication, December 6, 2016; 10.1038/leu.2016.372 Full Text | | | | High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALLS K Tasian, C Hurtz, G B Wertheim, N G Bailey, M S Lim, R C Harvey, I-M Chen, C L Willman, R Astles, A Zebrowski, S C Reshmi, M M Li, N V Frey, S M Luger, M Carroll and A E Perl Leukemia 2017 31: 981-984; advance online publication, December 9, 2016; 10.1038/leu.2016.375 Full Text | | | | CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin DH Bruns, M Böttcher, M Qorraj, M Fabri, S Jitschin, J Dindorf, L Busch, R Jitschin, A Mackensen and D Mougiakakos Leukemia 2017 31: 985-988; advance online publication, December 23, 2016; 10.1038/leu.2016.378 Full Text | | | | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patientsD Rossille, I Azzaoui, A L Feldman, M J Maurer, G Labouré, M Parrens, C Pangault, T M Habermann, S M Ansell, B K Link, K Tarte, T E Witzig, T Lamy, S L Slager, M Roussel, N Milpied, J R Cerhan and T Fest Leukemia 2017 31: 988-991; advance online publication, January 27, 2017; 10.1038/leu.2016.385 Full Text | | | | PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myelomaS Panchabhai, I Schlam, S Sebastian and R Fonseca Leukemia 2017 31: 991-994; advance online publication, December 27, 2016; 10.1038/leu.2016.389 Full Text | | | | HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemiaP Mehdipour, F Santoro, O A Botrugno, M Romanenghi, C Pagliuca, G M Matthews, R W Johnstone and S Minucci Leukemia 2017 31: 995-997; advance online publication, January 24, 2017; 10.1038/leu.2017.3 Full Text | | | | Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study OPENH Ludwig, K Weisel, M T Petrucci, X Leleu, A M Cafro, L Garderet, C Leitgeb, R Foa, R Greil, I Yakoub-Agha, D Zboralski, S Vauléon, T Dümmler, D Beyer, A Kruschinski, K Riecke, M Baumann and M Engelhardt Leukemia 2017 31: 997-1000; advance online publication, January 11, 2017; 10.1038/leu.2017.5 Full Text | | | | Gain of function in Jak2V617F-positive T-cellsG Nishanth, D Wolleschak, C Fahldieck, T Fischer, A Mullally, F Perner, T M Schnöder, S Just, F H Heidel and D Schlüter Leukemia 2017 31: 1000-1003; advance online publication, January 11, 2017; 10.1038/leu.2017.6 Full Text | | | | Myelodysplastic syndromes and bone loss in mice and menH Weidner, M Rauner, F Trautmann, J Schmitt, E Balaian, A Mies, S Helas, U Baschant, C Khandanpour, M Bornhäuser, L C Hofbauer and U Platzbecker Leukemia 2017 31: 1003-1007; advance online publication, January 11, 2017; 10.1038/leu.2017.7 Full Text | | | | Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALLV Serafin, V Lissandron, B Buldini, S Bresolin, M Paganin, F Grillo, N Andriano, C Palmi, G Cazzaniga, S Marmiroli, V Conter, G Basso and B Accordi Leukemia 2017 31: 1007-1011; advance online publication, January 13, 2017; 10.1038/leu.2017.13 Full Text | | | | Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study GroupN Jahn, M Agrawal, L Bullinger, D Weber, A Corbacioglu, V I Gaidzik, L Schmalbrock, F Thol, M Heuser, J Krauter, G Göhring, A Kündgen, W Fiedler, M Wattad, G Held, C-H Köhne, H-A Horst, M Lübbert, A Ganser, R F Schlenk, H Döhner, K Döhner and P Paschka Leukemia 2017 31: 1012-1015; advance online publication, January 16, 2017; 10.1038/leu.2017.18 Full Text | | | | Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidenceM Baccarani Leukemia 2017 31: 1015-1016; advance online publication, February 3, 2017; 10.1038/leu.2017.20 Full Text | | Correspondence | Top | | Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein depletionD Fahrenkamp, O Herrmann, S Koschmieder, T H Brümmendorf and M Schemionek Leukemia 2017 31: 1017-1019; advance online publication, February 7, 2017; 10.1038/leu.2017.19 Full Text | | | | Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantationS Kobayashi, A Kobayashi, Y Osawa, S Nagao, K Takano, Y Okada, N Tachi, M Teramoto, T Kawamura, T Horiuchi, S Kato, T Maekawa, T Yamamura, J Watanabe, Y Harada, H Harada, K Sato and F Kimura Leukemia 2017 31: 1020-1022; advance online publication, February 14, 2017; 10.1038/leu.2017.44 Full Text | | | | | | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | | | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. | | | |
No comments:
Post a Comment